Chelsea Therapeutics, Inc. Announces Initiation of Investigator-Led Phase II Study of Droxidopa in Chronic Fatigue Syndrome

CHARLOTTE, N.C., Aug. 19, 2010 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) announced that a new investigator-led phase II clinical study of Droxidopa, an oral synthetic precursor of norepinephrine, has been initiated in chronic fatigue syndrome (CFS).